Wed. 8 May 2024, 5:21pm ET
Benzinga
Earnings, Earnings Misses, News
Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly sales of $143.600 million which missed the analyst consensus estimate of $145.832 million by 1.53 percent. This is a 6.61 percent decrease over sales of $153.764 million the same period last year.